ATTIVO
Sponsor Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Version 1.0 28.05.2018
Objective To assess antitumor activity and safety of atezolizumab as treatment in a cohort of pretreated, advanced non-small cell lung cancer (NSCLC) patients with
rare histological subtypes
Study design This is an open-label, multicentre, phase II study evaluating the activity and safety of atezolizumab in a cohort of pretreated, advanced non-small cell lung cancer
(NSCLC) patients with rare histological subtypes
Number of Patients Total number of patients: 43 patients at 10 national Centers
STRUTTURA DI RIFERIMENTO
Ospedale S.Maria della Misericordia - Centro Operativo Studi Clinici S.C.Oncologia Medica